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Early diagnosis and initiation to appropriate treatment is vital for tuberculosis (TB) control.
The XpertMTB/RIF (Xpert) assay offers rapid TB diagnosis and quantitative estimation of
bacterial burden throughCycle threshold (Ct) values. We assessed whether the XpertCt
value is associated with delayed TB diagnosis as a potential monitoring tool for TB control
programme performance.
Materials andMethods
This analysis was nested in a prospective study under the routine TB surveillance proce-
dures of the National TB Control Program in Manhiça district,Maputo province, Mozam-
bique. Presumptive TB patients were tested using smear microscopy and Xpert.We
explored the association between XpertCt values and self-reporteddelay of Xpert-positive
TB patients as recorded at the time of diagnosis enrolment. Patients with >60 days of TB
symptomswere considered to have long delays.
Results
Of 1,483 presumptive TB cases, 580 were diagnosed as TB of whom 505 (87.0%)were due
to pulmonaryTB and 302 (94.1%)were Xpert positive. Ct values (range, 9.7–46.4) showed
a multimodal distribution. The median (IQR) delay was 30 (30–45) days. Ct values showed
no correlationwith delay (R2 = 0.001, p = 0.621), nor any association with long delays:
adjusted odds ratios (AOR) (95% confidence interval [CI]) comparing to >28 cycles 0.99
(0.50–1.96; p = 0.987) for 23–28 cycles, 0.93 (0.50–1.74; p = 0.828) for 16–22 cycles; and
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1.05 (0.47–2.36; p = 0.897) for <16 cycles. Being HIV-negative (AOR [95%CI]), 2.05 (1.19–
3.51, p = 0.009) and rural residence 1.74 (1.08–2.81, p = 0.023), were independent predic-
tors of long delays.
Conclusion
XpertCt values were not associated with patient delay for TB diagnosis and cannot be used
as an indicator of TB control program performance.
Introduction
Tuberculosis (TB) remains a global health burden and caused 1.5 million deaths in 2014 glob-
ally [1]. Early diagnosis and initiation of effective TB treatment are vital for bringing down TB
transmission [2,3]. Delays in diagnosing TB hamper effective TB control, and TB control pro-
grammes aim for reducing such delays as much as possible [4]. A readily available measure of
diagnostic delay would help TB control programmes in monitoring their performance in this
respect.
The Xpert MTB/RIF assay (Xpert), a cartridge-basedreal-time PCR, offers rapid diagnosis
of susceptible TB and resistance-conferringmutations to rifampicin in the rpoB gene within 2
hours of testing. The Xpert technology also offers a quantitative estimation of bacterial burden
in form of cycle threshold (Ct) values. Ct values have been found to predict decreasing bacterial
burden with increasing immunosuppression and a combination of Ct values and sputum
smear status to be a possible measure of bacterial burden in high HIV-burden settings [5]. Sev-
eral studies have documented the various factors associated with patient delay for TB diagnosis
[6,7,8,9,10,11,12,13,14].Mycobacterial load is likely to increase with patient delay since bacil-
lary burden has been found to grow over time and may have an impact on the novel diagnostic
tests [15,16].
Mozambique with a population of 27 million people in 2014, has low case detection rate,
below 50%[17], the estimated TB incidence is around 551 cases per 100,000 population; of
these cases, an estimated 58% are HIV co-infected [18]. By 2014, 24 Xpert machines were oper-
ating in the country [1]. A study done in Beira city of Mozambique found the median patient
delay for TB diagnosis to be 61 days (28–113)[19].
This study aimed at analyzing whether Ct values are correlated with diagnostic delays and/
or associated with long delays among patients referred for Xpert testing in Mozambique. If




The current study was nested in a prospective surveillancebased study embedded in the rou-
tine TB patient management procedures of the National TB Control Program for the district of
Manhiça, a high TB and HIV burden area in SouthernMozambique [20,21]. The study was
conducted by the Manhiça Health Research Center (Centro de Investigação em Saude de Man-
hiça, CISM) located adjacent to the Manhiça District Hospital, where a majority of the pre-
sumptive TB cases from peripheral health centres in the district are referred for diagnosis.
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Study participants
The study enrolled consecutively presumptive TB cases referred for TB diagnosis at the Man-
hiça District Hospital from 11 health care centers betweenAugust 2013 and August 2014. A
presumptive TB case was defined as someone presenting with cough for more than 2 weeks
and/or weight loss and/or fever and/or night sweats for more than two weeks, regardless of
having been previously treated for TB. Although Xpert was not routinely used in the country at
that time, it was used in this research context, together with AFB smear on Ziehl Neelsen
microscopy, as an initial test for any specimen (mostly sputa) provided by a presumptive TB
case. Culture was only done for diagnosis in TB previously treated patients (formerWHO Cat-
egory 2 patients) or new TB cases who were AFB smear positive at month 5 of follow up. AFB
smears were processed in the Biosafety Level III TB laboratory at CISM. On a ratio of 1:2 mL of
sample to sample reagents, incubated at room temperature for 15 minutes, 1 mL of the mixture
was added to the Xpert cartridge and analyzed in Xpert system according to manufacturer’s
guide. Xpert Ct values were taken as the mean of PCR cycles obtained from the five probes
(A-E) of the Xpert machines. Ct values inversely correlate with bacterial load i.e. lower Ct val-
ues represent a higher starting concentration of DNA template whereas higher Ct values repre-
sent a lower concentration of DNA template. The mean Ct values are also categorized by the
Xpert system semi-quantitatively in relation to sample positivity as very low (>28 cycles), low
(23–28 cycles), medium (16–22 cycles) and high (<16 cycles)[22].
Study specific questionnaires were implemented to capture the most important variables.
Demographic and clinical data were collected at enrolment.
Operational definitions
Patient delay for TB diagnosis was defined as reported total duration of symptoms at the time
of study enrolment. By the time of enrolment the patient could have had several diagnostic vis-
its to the clinic where the current TB diagnosis was made, as well as sought care from several
health services providers. For these reasons as well as the wide variation in literature about
patient delay for TB diagnosis [6,7,8,9,10,11,12,13,14],we operationalized long delay to
be 60 days with TB symptoms before TB diagnosis before TB diagnosis before current study
data analysis. This was considered as delay long enough to significantly impact on the TB con-
trol programmes.
We considered cough as the main symptom and if absent, duration of the other TB symp-
tom(s) was considered. For the current analysis, a TB case was defined as a study participant
positive with Xpert test.
Datamanagement and analysis
The data collected from presumptive TB cases and TB cases were kept in paper forms (CRFs),
which were checked by the study coordinators and study nurse at the end of each week for
quality assurance. Completed forms were double computer-entered at CISM. Data were
exported to Stata, (Stata Corp LP, College Station TX,USA) for analysis of frequencies and pro-
portions of participants’ characteristics and median symptom duration were compared. We
used theWilcoxon ranksum test and the Kruskall-Wallis test to compare delays between
groups, and Spearman’s correlation coefficient to express the correlation between delays and
Ct values. In the analysis of long delays we adjusted the association between categorized Ct val-
ues and delays of60 days duration for confounding variables in a multivariate logistic regres-
sion model. In a secondary analysis we explored independent associations with long delays by
including in a similar model all covariates with a p-value<0.2 at univariate analysis, using
XpertCt Values, Patient Delays, TB Diagnosis
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back-ward elimination to arrive at a final model that contained variables with a p-value<0.05.
Reportedmodel p-values were based on the likelihood ratio test.
Ethical consideration
The study was approved by the CISM’s Internal Scientific Committee, CISM’s Institutional
Bioethics Committee for Health (CIBS—Comité Institucional de Bioética para a Saúde) and
the National Bioethics Committee for Health (CNB—ComitéNacional de Bioética para a




A total of 1483 presumptive TB cases were enrolled in the current study of whom 580 were
diagnosed as TB. 505(87.0%) were due to pulmonary TB, 204 (40.4%) of whom were smear
positive and 321 (63.6%) were positive for Xpert, Fig 1.
Of the 321 Xpert positive TB patients recorded, data for Ct value were available for 302 TB
patients of whom 176 (58%) were male, median age was 35 (interquartile range 33–37) years,
154 (51%) were from urban areas of the district 222 (74%) were HIV-positive and 14 (4.6%)
had rpoBmutation. The patient characteristics and median delay are shown in Table 1.
Fig 1. Flow diagramshowingXpertMTB/RIF test positive tuberculosis participants. TB = tuberculosis,
EPTB = extra pulmonary tuberculosis, PTB = pulmonary tuberculosis.
doi:10.1371/journal.pone.0162833.g001
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Table 1. Demographic and clinical-demographiccharacteristics and diagnostic delay of pulmonary TB patients.
Characteristic Frequency, n (%) Diagnostic delay Median (IQR) P value
Sex
Female 126(41.7) 30 (30–60)
Male 176 (58.3) 30 (30–60) 0.555
Age category
35 146 (48.5) 30 (30–60)
>35 155 (51.5) 30 (30–45) 0.934
Median age (IQR) 35 (33–37)
Residence
Urban 154 (51.0) 30 (30–30)
Rural 148 (49.0) 60 (30–60) 0.041
History of TB treatment
New 254 (84.1) 30 (30–45)
Previously treated 48 (15.9) 45(30–60) 0.177
Presence of cough
Yes 290 (96.0) 30 (7–131)
No 12 (4.0) 30 (30–53) 0.834
Fever
Yes 248 (82.1) 30 (30–60) 0.854
No 54 (17.9) 30 (30–60)
Night sweats
Yes 246 (81.7) 30 (30–60)
No 55 (18.3) 30 (30–60) 0.790
HIV-status
Positive 222 (74.5) 30 (30–60)
Negative 76 (25.5) 60 (30–60) 0.093
ONART
Yes 80 (36.0) 30 (30–60) 0.160
No 142 (64.0) 30 (30–30)
CD4 cell count
>200 cells/mm3 84 (44.9) 30 (30–45)
100–200 cells/mm3 35 (18.7) 30 (30–60) 0.708
<100 cells/mm3 68 (36.4) 30 (30–41) 0.729
Taking cotrimoxazole
Yes 28 (14.1) 30 (21–60)
No 170 (85.9) 30 (30–30) 0.825
Smear results
Negative 119 (39.7) 30 (30–30) 0.086
Positive 181 (60.3) 30 (30–60)
XpertMTB/RIF Ct value
Very low (>28 cycles) 73 (24.2) 30 (30–60)
Low (23–28 cycles) 75 (24.8) 30 (30–60) 0.562
Medium (16–22 cycles) 114 (37.7) 30 (30–60) 0.991
High (<16 cycles) 40 (13.3) 30 (30–60) 0.951
TB = tuberculosis, IQR = Interquartile range. Ct = cycle threshold
doi:10.1371/journal.pone.0162833.t001
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Distribution of patient delay and Ct values
Symptom duration showed a skewed distribution with a median of 30 days and an interquartile
range of 30 to 45 days,Fig 2a; 37% had medium (16–22 cycles) Xpert Ct values. Ct values
showed a multimodal distribution with peaks around values of 15, 25 and 33 cycles, Fig 2b.
There was no correlation betweenCt values and delays (Spearman R2 = 0.001, p = 0.612, Fig 3).
Log-transforming the delays did not improve the correlation (R2<0.001, p = 0.798).
Association of long diagnostic delay with Ct values
In univariate analysis, Xpert Ct values showed no significant association with long delays, with
adjusted odds ratios (AOR) (95% confidence interval [CI]) comparing to>28 cycles 0.99
(0.50–1.96; p = 0.987) for 23–28 cycles, 0.93 (0.50–1.74; p = 0.828) for 16–22 cycles; and 1.05
(0.47–2.36; p = 0.897) for<16 cycles. After multivariate adjustment for confounding by resi-
dence and HIV status the association remained absent, Table 2.
Predictors of long diagnostic delay
Delays (median, IQR) differed significantly between patients residing in rural parts of the dis-
trict (60, 30–60) and patients residing in urban parts (30, 30–30; p = 0.041). There were no sig-
nificant differences among other demographic and patient characteristics (Table 1).
Factors associated with long patient delay in the multivariate analysis also included being
HIV-negative (AOR [95% CI]), 2.05 (1.19–3.51, p = 0.009) and residence in rural area of Man-
hiça district 1.74 (1.08–2.81, p = 0.023), Table 2.
Discussion
We found that among pulmonary TB patients in Manhiça district of Mozambique referred for
Xpert testing, Xpert Ct values were not associated with the reported duration of TB symptom
duration, nor did they predict long delays for TB diagnosis of>60 days. Long delays were inde-
pendently associated with rural residence and HIV-negative status.
Fig 2. 2a: Distribution of the reportedsymptomduration, Fig2b: Distribution of the XpertmeanCt values.
doi:10.1371/journal.pone.0162833.g002
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Few studies have looked at additional information that can be generated from routine use of
the Xpert assay to inform TB control programs. Previous study found Xpert Ct values to corre-
late with bacillary burden in the lungs, i.e. increasing bacillary load with decreasing Xpert Ct
values [5]. Measures to estimate patient delay independently from what is reported by the
patient would be useful as a tool for monitoring TB control program performance with regard
to reducing diagnostic delays. Clearly, Xpert Ct values cannot be used for this purpose.
Fig 3. Scatter plot of individuals’meanCT value among those testingXpertMTB/RIF positiveby reportedsymptom
duration (SpearmanR2 = 0.001, p = 0.612).
doi:10.1371/journal.pone.0162833.g003
Table 2. Multivariate predictors of patient delay for TB diagnosis in Manhiçadistrict,Maputo
Mozambique.
Variables Odds ratio P value [95%CI]
Ct 23–28 Cycles 0.99 0.987 0.504–1.962
Ct 16–22 Cycles 0.93 0.828 0.499–1.745
Ct <16 Cycles 1.05 0.897 0.471–2.362
HIV-negative 2.05 0.009 1.193–3.512
Rural residence 1.74 0.023 1.078–2.811
Ct = cycle threshold, CI = Confidence interval
doi:10.1371/journal.pone.0162833.t002
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The lack of observed association betweenCt values and diagnostic delays may imply that
longer delays do not lead to higher bacterial burden, at least not at individual patient level, and
that it is the individual clinical trajectory rather than duration of disease that predicts the bacte-
rial burden at diagnosis [23,24]. Alternatively, or in addition, it may imply that the reported
duration of symptoms does not reflect the duration of disease. This may be due to poor recall
by patients and/or relatively long and variable periods of subclinical disease before symptoms
arise[25], although subclinical disease is more likely to be missed in routine than in provider-
initiated symptom screening for tuberculosis [26]. We investigated other predictors of patient
delay for TB diagnosis and found rural residence and beingHIV-negative to predict patient
delay for TB diagnosis. It is worth noting that Xpert testing in Manhiça is only available in the
district town, so rural patients first need to be referred and then take time to travel to town for
the Xpert test. This was in agreement with a previous study that found rural residence as a risk
factor of patient delay for TB diagnosis [13,27]. Previous studies documentedHIV-positive
individuals to have less patient delay compared to HIV-negative [12,28]. Previous studies have
noted that HIV-positive individuals are more likely to suffer serious TB symptoms which
prompt them to seek care earlier than HIV-negative individuals [26,28]. An alternative hypoth-
esis is that TB patients who are HIV-positive and wait too long to be diagnosed die at home.
Since there is capacity for smear microscopy in peripheral health centers in Manhiça district,
replacing AFB with centralizedXpert may increase TB diagnostic delays [29].
Our study has some limitations. First, the delay as reported by patients was retrospectively
analysed from the collected data. The reported duration may have suffered from recall bias for
delays and “digit preference” (e.g. 2 weeks, 2 months) in delay ascertainment. Secondly, the
findingsmay not represent delays among presumptive TB patients in Mozambique, but rather
a selection of patients in the district referred for Xpert reflecting the local diagnostic and refer-
ral algorithm. This limits the conclusions drawn from our secondary analysis but not from our
primary analysis, since the latter aimed to look at a biological phenomenon that is expected to
exist independent of representativeness of the patients included in the current study. We did
not collect data concerning the intervals of health care contacts to the current study yet patients
may have contacted other health care facilities and received antibiotics, which may have
resolved partly some TB symptoms before the current visit. Finally, we took the mean CT val-
ues from the five probes of Xpert Ct for predicting patient delay and had low prevalence 14/
302 (4.6%) of rpoBmutation, however, in settings with high rifampicin resistance, these may
be analysed separately or participants eliminated from the analysis as rifampicin resistance
may alter the results.
In conclusion, in our study Xpert Ct values did not predict patient delay for TB diagnosis,
and are not useful for monitoring TB control program performance with regard to reducing
diagnostic delay.
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